BTIG increased its price target for Cullinan Therapeutics to $40, reflecting a potential 93% upside from the current stock price of around $20.73. This upgrade follows successful Phase 3 trial results for zipalertinib, a treatment for non-small cell lung cancer, which showed a significant 6-month improvement in progression-free survival when combined with chemotherapy. The positive trial outcome boosts confidence in Cullinan's cancer therapy pipeline and may drive future stock gains. The company shared these results at a recent oncology conference and investor event.
Cullinan Therapeutics is noted for its recent positive Phase 3 lung cancer trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 00:02 WIB: Among 91 priced US health stocks, 76 advanced and 14 declined. Notable movers include AMWL at USD 13.65 (+5.04%), DNA at USD 7.09 (+5.04%), and TDOC at USD 6.47 (+5.03%).
Remittix has raised $33 million in its presale, nearing its $36 million hard cap ahead of its November 24, 2026 launch. The project offers a PayFi ecosystem connecting crypto with bank payments, with active product use and testing underway. Meanwhile...
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
XAI Floating Rate & Alternative Income Trust announced it will hold its Q3 2026 quarterly webinar on November 2, 2026, featuring a Q&A session with senior leaders from XA Investments and King Street Capital Management. The Trust focuses on generating...
